Integration of Biological Sciences in Modern Healthcare: A Narrative Review with Critical Synthesis

Ashutosh Kumar Yadav; Reetu Reetu

Ashutosh Kumar Yadav Dr Shakuntala Misra National Rehabilitation University Lucknow
Reetu College of Pharmacy, Integral University, Lucknow

Abstract

Background: The convergence of biological sciences with clinical medicine has fundamentally reshaped modern healthcare. Advances in molecular biology, genomics, pharmacology, and biotechnology have driven a transition from symptom-based practice toward predictive, preventive, and personalised care.

Objectives: This narrative review critically examines how core biological science disciplinesincluding molecular biology, pharmacology, biotechnology, immunology, and systems biologyare integrated into contemporary healthcare, and evaluates their translational achievements and remaining limitations.

Methods: A narrative review approach with critical synthesis was employed. Literature searches were conducted in PubMed/MEDLINE, Scopus, and Google Scholar, covering peer-reviewed publications from 2001 to 2024, with emphasis on studies published after 2018. Thematic synthesis was used to organise findings across five core domains.

Results: Biological sciences underpin critical innovations in early disease detection (liquid biopsy, CRISPR-based diagnostics), drug development (target-based screening, biologics, antibody-drug conjugates), and therapeutic delivery (nanoparticle systems, gene therapy, CAR-T cells). Personalised medicine, driven by multi-omics integration and artificial intelligence, represents the most transformative frontier, as demonstrated by approved CRISPR therapeutics, mRNA vaccines, and circulating tumour DNA-guided oncology.

Conclusion: Despite remarkable progress, challenges including equitable access, data governance, regulatory complexity, and translational lag persist. Closing these gaps will require interdisciplinary collaboration, diversified research cohorts, and evidence-based policy reform.

Keywords: biological sciences, translational medicine, genomics, personalised medicine, gene therapy, pharmacogenomics, multi-omics, liquid biopsy, CRISPR, nanomedicine

Downloads

Download data is not yet available.

References

1. Lander ES, Linton LM, Birren B, et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921. doi:10.1038/35057062
2. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175. doi:10.1016/j.immuni.2005.06.008
3. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
4. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56. doi:10.1038/s41591-018-0300-7
5. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83. doi:10.1186/s13059-017-1215-1
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. doi:10.1056/NEJM200104053441401
7. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
8. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
9. Swen JJ, van der Wouden CH, Manson LE, et al. A 12-gene pharmacogenomic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet. 2023;401(10374):347–356. doi:10.1016/S0140-6736(22)01841-4
10. Gregg AR, Van den Veyver IB, Gross SJ, et al. Non-invasive prenatal screening by next-generation sequencing. Annu Rev Genomics Hum Genet. 2021;22:361–390. doi:10.1146/annurev-genom-083118-015053
11. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229–236. doi:10.1038/s41586-020-1978-5
12. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260. doi:10.1056/NEJMoa2031054
13. Baethge C, Goldbeck-Wood S, Mertens S. SANRAa scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. doi:10.1186/s41073-019-0064-8
14. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369–1372. doi:10.1126/science.1259657
15. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023–1031. doi:10.1038/nbt.2696
16. Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272. doi:10.1056/NEJMoa2200075
17. Moran S, Martínez-Cardús A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(10):1386–1395. doi:10.1016/S1470-2045(16)30297-2
18. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727–730. doi:10.1038/nrd892
19. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nat Rev Drug Discov. 2015;14(10):735–736. doi:10.1038/nrd4596
20. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860. doi:10.1016/S0140-6736(17)31868-8
21. Al-Zaidy SA, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J Neuromuscul Dis. 2019;6(3):307–317. doi:10.3233/JND-190387
22. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
23. Rojas LA, Sethna Z, Soares KC, et al. Personalised RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–150. doi:10.1038/s41586-023-06063-y
24. Kather JN, Krisam J, Charoentong P, et al. Predicting survival from colorectal cancer histology slides using deep learning: a retrospective multicenter study. PLOS Med. 2019;16(1):e1002730. doi:10.1371/journal.pmed.1002730
25. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224. doi:10.1038/s41588-018-0183-z
26. All of Us Research Program Investigators. The 'All of Us' Research Program. N Engl J Med. 2019;381(7):668–676. doi:10.1056/NEJMsr1809937
27. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
28. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–157. doi:10.1038/s41586-019-1711-4
29. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2
30. Din MO, Danino T, Prindle A, et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature. 2016;536(7614):81–85. doi:10.1038/nature18930.